Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Sees Large Drop in Short Interest

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 33,053 shares, a decrease of 59.6% from the September 30th total of 81,750 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 679,428 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

CHGCY has been the topic of several recent analyst reports. UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Nomura raised Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Chugai Pharmaceutical has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Up 2.4%

Shares of CHGCY stock opened at $21.66 on Friday. The stock has a fifty day moving average of $20.73 and a 200 day moving average of $24.52. Chugai Pharmaceutical has a 52 week low of $18.33 and a 52 week high of $34.84. The firm has a market capitalization of $71.29 billion, a price-to-earnings ratio of 22.03 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Tuesday, October 27th. The company reported $0.27 earnings per share for the quarter. The business had revenue of $2.54 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Chugai Pharmaceutical had a net margin of 35.63% and a return on equity of 24.91%. Equities research analysts anticipate that Chugai Pharmaceutical will post 1.00 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.